Sign in
Taking people in United StatesNo phase

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

Key facts

Who runs it
Weill Medical College of Cornell University
Where
Brooklyn and New York, United StatesSee the 3 sites
Trial code
Status
Recruiting
People taking part
510 people, planned
Started
1 Jul 2021
Planned end
30 Jul 2026
Type of study
Observational
Treatments tested
  • Cardiac MRI
  • Echocardiogram
  • 6-minute walk test
  • Questionnaire
Record updated
22 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Emergency room presentation and/or hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea/vomiting, myalgias, fever, syncope/presyncope

Who cannot take part

  • Inability to provide informed consent (e.g. cognitive impairment)
  • Unrelated condition (e.g. neoplasm) with life expectancy <12 months prohibiting follow-up
  • Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate < 30 ml/min/1.73m2) will undergo non-contrast MRI but will not be excluded from this study
  • Contraindication to CMR (i.e. non-compatible pacemaker/defibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) <30 ml/min/1.73m2)
  • Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol

This trial is currently available in United States.

  • New York-Presbyterian/Brooklyn Methodist HospitalBrooklyn, United StatesContact: Marline Attallah, MDTaking people
  • New York Presbyterian QueensNew York, United StatesContact: Susan IngenitoTaking people
  • Weill Cornell Medicine-New York Presbyterian HospitalNew York, United StatesContact: Elizabeth Manowitz, BSTaking people

About the trial

What the trial wants to find out

The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.

The group in the trial

  • Diagnosed with COVID-19

    Participants in the study cohort will have been diagnosed with COVID-19 by a PCR (polymerase chain reaction) positive test

    Treatment: Cardiac MRI, Echocardiogram, 6-minute walk test, and Questionnaire

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors
Record updated
22 January 2026